Last reviewed · How we verify

AZD4144 — Competitive Intelligence Brief

AZD4144 (AZD4144) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K delta and PI3K gamma inhibitor. Area: Oncology.

phase 2 PI3K delta and PI3K gamma inhibitor PI3K delta and PI3K gamma Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AZD4144 (AZD4144) — AstraZeneca. AZD4144 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZD4144 TARGET AZD4144 AstraZeneca phase 2 PI3K delta and PI3K gamma inhibitor PI3K delta and PI3K gamma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K delta and PI3K gamma inhibitor class)

  1. AstraZeneca · 6 drugs in this class
  2. Aclaris Therapeutics, Inc. · 1 drug in this class
  3. Astellas Pharma Global Development, Inc. · 1 drug in this class
  4. Southern Europe New Drug Organization · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZD4144 — Competitive Intelligence Brief. https://druglandscape.com/ci/azd4144. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: